The anxiety some users experience may stem from rapid metabolic shifts, appetite suppression intensity, or underlying genetic differences in how their bodies process the medication
This supports mechanistic studies into receptor trafficking, drug binding, and signaling particularly in immunometabolic areas like pancreatic islets and inflamed adipose tissue
Wolfe, D., Rosenstein, B., & Fortin, M
Peptide selection
Reevaluate metabolic status prior to discontinuing and restarting GLP-1 therapy, measure HbA1c, electrolytes, and fasting glucose and document any insulin requirements to assist in safe resumption
A 74-year-old male with type 2 diabetes, atrial fibrillation, coronary artery disease, and obesity (BMI 31.7) presented with severe epigastric pain and was diagnosed with severe pancreatitis